|
Trellus Health PLC on Monday reported a narrowed pretax loss during the first half of 2025, as it continues to pursue additional fundraising to prolong its cash runway. The London-based healthcare company said its pretax loss for the six months that ended June 30 narrowed to $3.0 million from $3.9 million the year before. This was largely due to administrative expenses reducing by 20% to $3.3 million from $4.1 million. Revenue multiplied to $295,000 from $50,000. Shares in Trellus Health tumbled 46% to 0.43 pence in London on Monday morning. The stock is down 63% over the past year. ‘We are very proud of what we have achieved year-to-date, further reducing our cost base, while successfully building a new clinical trial vertical and advancing our broader strategic evolution. By aligning closely with our partners’ immediate needs and financial priorities, we have strengthened our position as a valuable partner,’ said Chief Executive Officer Marla Dubinsky. ‘Our evidence-based suite of services for pharma improves adherence, persistence and engagement, while also delivering key real-world behavioural insights, all essential drivers of success across their end-to-end business. We expect to announce at least one new collaboration by November and confirm the board’s intention to explore a possible fundraise over the coming weeks to scale our commercial strategy.’ Trellus Health said available cash resources totalled $1.6 million, against $4.1 million at December 31. 2024. This will provide runway into early November, the company added, confirming its intention to explore a possible fundraising over the coming weeks. ‘The directors have taken steps to reduce outgoings and continue to evaluate all commercial options in a way that maximises its value, including ongoing discussions with a number of potential commercial partners,’ Trellus Health explained. The board is ‘optimistic’ in being able to obtain funding to extend its cash runway for at least 12 months, but noted there is no guarantee. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
